PRAX$301.54

PRAX is up +7.88% today on strong T1/T2 catalysts: FDA Breakthrough Therapy designation for Elsunersen and an extended NDA review date for Relutrigine. The stock broke its 15-min opening range (281.67-289.50) on 5.4x volume and is currently trading at 300.10, well above the initial breakout level. The stop at 281.67 remains intact and provides a defined risk floor. The thesis (catalyst-driven momentum) is active and unbroken. No reason to exit or adjust yet.

PRAX is up 12.67% today on a confirmed T1 SEC filing (8-K) and a major FDA Breakthrough Therapy designation for Elsunersen, plus an extended NDA review date for Relutrigine. The position is up 12.67% (39 pts), well past the initial stop distance of 31.77 pts, so the trailing stop is already set at 281.67. The thesis remains intact with strong fundamental catalysts and heavy volume support. No reason to sell or adjust exits; hold for the 340 target.

PRAX broke its 15-min opening range (281.67-289.50) on 5.4x volume, closing at 300.72. The move is backed by a T1 SEC filing (8-K) for results of operations, providing a fundamental catalyst for the surge. The price action shows strong momentum (+3.8% from OR high to close) with heavy volume support. The stop at the opening range low (281.67) is 6.3% below entry, offering a defined risk with significant upside to the next resistance level around 340. This is a high-conviction momentum play driven by a confirmed catalyst.

5 sh @ $304.11 ($1,520.53) · stop $281.67 · target $340.00